Diagnostics for the Frontlines of Healthcare

Diagnostics that Break Barriers

Hemex Health is working to empower the frontlines of healthcare with our inexpensive, portable, and easy-to-use diagnostic device - Gazelle®.   Gazelle provides affordable, accurate testing to new populations at sites where it is needed most. Hemex designs products for the real world by listening to the needs of providers including those located in remote and challenging settings. Initial tests include sickle cell disease, beta thalassemia, and COVID-19.

Gazelle Hb Variant for Sickle Cell and Beta Thalassemia

Identifies hemoglobin disorders rapidly, easily, and inexpensively

Over seven percent of the world’s population is at risk of inheriting hemoglobin disorders, including sickle cell disease (SCD) and beta thalassemia.  Early diagnosis could prevent tens of thousands of child deaths each year. 

Gazelle Hb Variant is a miniaturized version of the gold standard test known as cellulose acetate electrophoresis. Administration of the test requires minimal training. Results are displayed in 8 minutes, including hemoglobin percentages by type, and can be stored locally or transmitted to the Cloud for patient and disease tracking.  

Gazelle COVID-19 FIA Test

Affordable, Accurate Test for ALL POINT-OF-CARE SETTINGS

The Gazelle COVID-19 Test is a fluorescent lateral flow immunoassay (FIA) for the qualitative detection of nucleocapsid antigen from COVID-19. The Reader uses advanced imaging and signal-to-noise enhancement techniques to high accuracy.